


WEDNESDAY  
**PROGRAMME**  
3 MAY 2023



**09:00 – 09:15**

**Welcome & Opening Address**

Michael Ison  
DMID/NIAID/NIH, Rockville, MD, USA

**09:15 – 10:00**

**Opening Keynote**

Chair: Michael Ison, DMID/NIAID/NIH, Rockville, MD, USA

**The Development of Small Molecules for the Treatment of Respiratory Viral Illnesses: Important Lessons From A Burgeoning New Era**

Richard Whitley  
University of Alabama, Birmingham, AL, USA

**SESSION**

**1**

**10:00 – 11:30**

**PRECLINICAL – VIRAL TARGETS**

Co-Chairs: Lieve Naesens, Rega Institute, Leuven, Belgium and Hui-Ling Yen, University of Hong Kong, Hong Kong SAR, China

**10:05 – 10:30**

**Insights from Coronavirus Replication in Developing Antivirals**

Mark Denison  
Vanderbilt University Medical Center, Nashville, TN, USA

**10:30 – 10:55**

**A Molecularly Modified Lectin for the Prevention and Treatment of Coronaviruses and Influenza**

David Markovitz  
University of Michigan, Ann Arbor, MI, USA

**10:55 – 11:20**

**Non-nucleoside RSV Polymerase Inhibitor**

Richard Plemper  
Georgia State University, Atlanta, GA, USA

**11:20 – 11:30**

**Panel Discussion**

**11:30 – 11:45 Coffee Break**

**SESSION**

**2**

**11:45 – 13:15**

**PRECLINICAL – HOST-DIRECTED ANTIVIRAL THERAPEUTICS**

Co-Chairs: Bin Cao, Capital Medical University, Beijing, China and Andres Pizzorno, International Center for Research in Infectious Diseases, Lyon, France

**11:50 – 12:15**

**Harnessing Interferon Responses as Potential Broad Spectrum Respiratory Antiviral Treatments**

Evangelos Andreakos  
Biomedical Research Foundation, Academy of Athens, Greece

**12:15 – 12:40**

**Towards a Novel Host-targeted Anti-infective Strategy for COVID-19 and Other Acute Respiratory Viral Diseases**

Stephan Ludwig  
Westfaelische-Wilhelms-University, Münster, Germany

**12:40 – 13:05**

**Combined Inhibition of Viral and Host Factors to Maximize Antiviral Activity**

Sara Cherry

University of Pennsylvania, Philadelphia, PA, USA

**13:05 – 13:15**

**Panel Discussion**

**13:15 – 14:15 Lunch and Poster Viewing**

**SESSION**

**3**

**14:15 – 15:45**

**ORAL ABSTRACT SESSION 1 – PRECLINICAL DEVELOPMENT**

Co-Chairs: Mark Denison, Vanderbilt University Medical Center, Nashville, TN, USA and Rich Whitley, University of Alabama, Birmingham, AL, USA

**14:15 – 14:30**

**Preclinical Antiviral Profile of ALG-097558, a Novel Pan-Coronavirus 3CL Protease Inhibitor (AASU0006)**

Andreas Jekle

Aligos Therapeutics, South San Francisco, CA, USA

**14:30 – 14:45**

**CD388, a Novel Drug Fc-Conjugate (DFC), Demonstrates Potent, Universal Activity Against Influenza A and B (AASU0009)**

James Levin

Cidara Therapeutics, San Diego, CA, USA

**14:45 – 15:00**

**A Pseudovirus-Based System for Mapping the Antigenic Effects of Thousands of Mutations in SARS-CoV-2 Spike (AASU0045)**

Bernadeta Dadonaite

Fred Hutchinson Cancer Center, Seattle, WA, USA

**15:00 – 15:15**

**Preclinical Development of Optimized DHODH Inhibitors as Broad-Spectrum Antivirals for the Treatment of Respiratory Virus Infections (AASU0039)**

Hella Kohlhof

Immunic AG, Gräfelfing, Germany

**15:15 – 15:30**

**Inhaled Muco-Trapping Monoclonal Antibody for Effective Therapy Against Respiratory Syncytial Virus Infections in Lambs (AASU0047)**

Sam Lai

University of North Carolina, Chapel Hill, NC, USA

**15:30 – 15:45**

**Live Imaging of Airway Epithelium Reveals Mucociliary Clearance Modulates Spread of SARS-CoV-2 (AASU0034)**

Mark Becker

Northwestern University, Chicago, IL, USA

**15:45 – 16:05 Coffee Break**

**SESSION****4****16:05 – 17:45****CLINICAL TRIAL DESIGN ISSUES/  
HUMAN CHALLENGE/OMICS**

Co-Chairs: Nelson Lee, University of Toronto, Toronto, Canada and  
Cameron Wolfe, Duke University Medical Center, NC, USA

**16:10 – 16:25****Randomized, Placebo Control Trials – Lessons from ACTT**

John Beigel  
NIAID/NIH, Rockville, MD, USA

**16:25 – 16:40****The RECOVERY Trial: Lessons and Legacy**

Peter Horby  
University of Oxford, Oxford, UK

**16:40 – 16:55****The SARS-CoV-2 Human Challenge Model**

Chris Chiu  
Imperial College, London, UK

**16:55 – 17:10****Use of Omics Approaches in the Context of Clinical Trials:  
Development of Improved Influenza Interventions**

Teresa Aydillo  
Icahn School of Medicine at Mount Sinai, New York, NY, USA


**17:10 – 17:25****Fully Remote Trials**

Caleb Skipper  
University of Minnesota, Minneapolis, MN, USA

**17:25 – 17:45****Panel Discussion**

---

THURSDAY  
PROGRAMME  
4 MAY 2023

**SESSION****5****8:30 – 10:45****UPDATES ON CLINICAL TRIALS**

Co-Chairs: David Hui, The Chinese University of Hong Kong, Hong Kong  
SAR, China and Helen Chu, University of Washington, Seattle, WA, USA

**08:35 – 09:05****Keynote Talk****REMAP-CAP: Preparing for the Pandemic and Translating  
the Network into Seasonal Threats**

Srinivas Murthy  
BC Children's Hospital, Vancouver, Canada

**09:05 – 09:25****Clinical Trials of Severe Viral Pneumonia**

Bin Cao  
China-Japan Friendship Hospital, Beijing, China

**09:25 – 09:45**

**Monoclonal Antibodies – Current State of the Art and Future Directions**

James Crowe

Vanderbilt University Medical Center, Nashville, TN, USA

**09:45 – 10:05**

**Antiviral Respiratory Viral Therapies for Children**

Janet Englund

Seattle Children's Hospital, Seattle, WA, USA

**10:05 – 10:25**

**Update on Clinical Trials: Small Molecules and Antibodies for RSV Management**

Angela Branche

University of Rochester Medical Center, Rochester, NY, USA

**10:25 – 10:45**

**Panel Discussion**

**10:45 – 11:05 Coffee Break**

**SESSION**

**6**

**11:05 – 12:35**

**ORAL ABSTRACT SESSION 2 – ANTIVIRALS, MONOCLONAL ANTIBODIES AND COMBINATIONS**

Co-Chairs: Emi Takashita, National Institute of Infectious Diseases, Tokyo, Japan and Tim Uyeki, CDC, Atlanta, GA, USA

**11:05 – 11:20**

**First-in-Human Study of CC-42344, a Novel Broad-Spectrum Influenza A Polymerase PB2 Inhibitor (AASU0024)**

Sam Lee

Cocrystal Pharma Inc., Bothell, WA, USA

**11:20 – 11:35**

**Safety and Efficacy Results from Phase 1 and 2a H1N1 Challenge Trials Using an Anti-Type A and B Influenza Immunotherapeutic that is also Synergistic with Oseltamivir in Mice (AASU0041)**

Thomas Luke

SAB Biotherapeutics, Sioux Falls, SD, USA

**11:35 – 11:50**

**CD388, a Novel Drug Fc-Conjugate (DFC), Demonstrates a High Barrier to Resistance and Retains Potent Activity Against Neuraminidase Inhibitor-Resistant Influenza A and B (AASU0008)**

Simon Döhrmann

Cidara Therapeutics, San Diego, CA, USA

**11:50 – 12:05**

**Exploratory Evaluation on the Effect of Ensitrelvir for Long COVID: a Post-Hoc Analysis of Phase 3 Part of Phase 2/3 in Patients with Mild-to-Moderate COVID-19 (AASU0012)**

Akimasa Fukushi


Shionogi & Co., Ltd, Osaka, Japan

**12:05 – 12:20**

**Clinical Trials of Inhaled Interferon Beta-1a (SNG001) in COVID-19 Patients in the Home and Hospital Settings (AASU0014)**

Phillip Monk

Synairgen Research Ltd, Southampton, Hants, UK



THURSDAY  
**PROGRAMME**  
4 MAY 2023

**12:20 – 12:35**

**Ensirelvir for Symptomatic and Mild Symptoms Only:  
COVID-19 Patients in Phase 2b/3 Part (AASU0010)**

Genki Ichihashi  
Shionogi & Co., Ltd, Osaka, Japan

**12:35 – 14:15**

**SPONSORED LUNCH SEMINAR**

**Combination Therapy to Treat Respiratory Infections:  
Ready for Primetime?**

**12:55 – 13:00**

**Introduction**

Michael Ison  
DMID/NIAID/NIH, Rockville, MD, USA

**13:00 – 13:20**

**The Challenges of Monotherapy – a View from the  
Immunocompromised Host**

Michael Boeckh  
Fred Hutchinson Cancer Center, Seattle, WA, USA

**13:20 – 13:40**

**Combination Antiviral Therapy for RVIs: Update on  
Clinical Progress**

Frederick Hayden  
University of Virginia School of Medicine, Charlottesville, VA, USA

**13:40 – 14:00**

**Antivirals plus Immune Modulators**

John Beigel  
NIAID/NIH, Rockville, MD, USA

**14:00 – 14:15**

**Panel Discussion**

**SESSION**

**7**

**14:15 – 16:15**

**CLINICAL TRIAL AND REGULATORY ISSUES**

Co-Chairs: Frederick Hayden, University of Virginia School of Medicine, Charlottesville, VA, USA and Michael Ison, DMID/NIAID/NIH, Rockville, MD, USA

**14:20 – 14:40**

**Regulatory Framework for Moving from EUA to FDA  
Approval for Antiviral Products**

Stephanie Troy  
US FDA, Silver Spring, MD, USA

**14:40 – 15:00**

**Clinical Trial Endpoints for Approval of Antiviral  
Therapeutics**

Marco Cavaleri  
EMA, Amsterdam, The Netherlands

**15:00 – 15:20**

**Combination Therapy**

Mariana Baz  
CHU de Québec-Université Laval, Québec, Canada

**SESSION****8****16:10 – 18:10****15:20 – 15:40****The Path Forward for the Treatment of Hospitalized Influenza Patients: Host-Targeted Therapeutics**

Kimberly Armstrong  
BARDA, Washington DC, USA

**15:40 – 15:50****Panel Discussion****15:50 – 16:10 Coffee Break & Poster viewing****TREATMENT UPDATES & ORAL ABSTRACT SESSION 3**

Co-Chairs: Kimberly Armstrong, Biomedical Advanced Research and Development Authority (BARDA), Washington DC, USA and Shikha Garg, CDC, Atlanta, GA, USA

**16:10 – 16:55****State of the Art of COVID-19 Therapy**

Cameron Wolfe  
Duke University Medical Center, Durham, NC, USA

**16:55 – 17:10****Comparison of the Effectiveness of Baloxavir Marboxil and Oseltamivir in Reducing Household Transmission of Influenza**

(AASU0004)

Takamichi Baba  
Shionogi & Co., Ltd, Osaka, Japan

**17:10 – 17:25****Heterogeneity of Influenza Infection Severity at Hospital Admission Significantly Confounds Analysis of Antiviral Effectiveness on Reducing Hospital Length of Stay (AASU0038)**

Aleda Leis  
University of Michigan, Ann Arbor, MI, USA

**17:25 – 17:40****Pharmacokinetics of an Extended Half-Life Monoclonal Antibody Against COVID-19 in Hematopoietic Stem Cell Transplant Recipients**

(AASU0007)

Jim Boonyaratanakornkit  
Fred Hutchinson Cancer Center, Seattle, WA, USA

**17:40 – 17:55****Trial in Progress: a Phase I/III, Randomised Controlled Pre-exposure Prophylaxis Study of the Anti-SARS-CoV-2 Antibody AZD3152 (SUPERNOVA) (AASU0016)**

Taylor Cohen  
AstraZeneca, Gaithersburg, MD, USA

**17:55 – 18:10****Meta-Analysis and Validation of OMICs Data from COVID-19 Patient Samples Reveal Auranofin as a Promising Therapeutic Agent (AASU0046)**

Shashank Tripathi  
Indian Institute of Science, Bengaluru, Karnataka, India

**18:10 – 19:10****Poster Reception and Poster viewing**

FRIDAY  
**PROGRAMME**  
5 MAY 2023



**08:30 – 08:40**

**Introduction to Roberts/Tisdale Lectureship**

Maria Zambon

UK Health Security Agency (UKHSA), London, UK / Chair of ISIRV

**08:40 – 09:25**

**Keynote Talk – Roberts/Tisdale Lectureship**

Co-Chairs: Frederick Hayden, University of Virginia School of Medicine, Charlottesville, VA, USA and Maria Zambon, UK Health Security Agency (UKHSA), London, UK

**Resistance to Antivirals Targeting Respiratory Viruses: When Does it Matter?**

Wendy Barclay

Imperial College, London, UK

**SESSION**

**9**

**09:25 – 10:55**

**THE RIGHT DRUG FOR THE RIGHT PATIENT: OPTIMIZING ANTIVIRAL TREATMENT**

Co-Chairs: Frederick Hayden, University of Virginia School of Medicine, Charlottesville, VA, USA and Maria Zambon, UK Health Security Agency (UKHSA), London, UK

**09:30 – 09:55**

**Role of Genomic Surveillance in Tracking Emergence of Resistance Over Time**

Adam Lauring

University of Michigan, Ann Arbor, MI, USA

**09:55 – 10:20**

**Understanding Infection and Immunity of SARS-CoV-2: from Diagnostics to Therapies**

Lisa Ng

A\* STAR Infectious Diseases Labs, Singapore

**10:20 – 10:45**

**Role of Misinformation and Erosion of Social Trust in Response to Pandemics**

Rachel Moran

University of Washington, Seattle, WA, USA

**10:45 – 10:55**

**Panel Discussion**

**10:55 – 11:15 Coffee Break**

**SESSION**

**10**

**11:15 – 12:45**

**ORAL ABSTRACT SESSION 4 – SURVEILLANCE & ANTIVIRAL RESISTANCE**


Co-Chairs: Nelson Lee, University of Toronto, Toronto, Canada and Arnold Monto, University of Michigan, Ann Arbor, MI, USA

**11:15 – 11:30**

**Implementation of Cell Culture-Based Assay IRINA for Baloxavir Susceptibility Monitoring, 2022-23 Influenza Season (AASU0018)**

Mira Patel

CDC, Atlanta, GA, USA



**11:30 – 11:45**

**ViralVar: A Web Tool for Multilevel Visualization of SARS-CoV-2 Genomes** (AASU0020)

Arghavan Alisoltani  
Northwestern University, Chicago, IL, USA

**11:45 – 12:00**

**Utilization of Whole Genome Sequencing to Augment Traditional Contact Tracing for a University SARS-CoV-2 Outbreak** (AASU0044)

Cameron Wolfe  
Duke University Medical Center, Durham, NC, USA

**12:00 – 12:15**

**Whole Genome Sequencing Exploring Evolution Associated with the Combined Effect of Oseltamivir and Favipiravir on Influenza Virus** (AASU0011)

Shengrui Mu  
China-Japan Friendship Hospital, Beijing, China

**12:15 – 12:30**

**Intra-host Population Dynamics of a SARS-CoV-2 Delta-Omicron Superinfection in an Immunocompromised Pediatric Patient** (AASU0021)

Lacy Simons  
Northwestern University, Chicago, IL, USA

**12:30 – 12:45**

**Altered RSV Population Structures in Adult Populations Following COVID-19 Mitigation Strategies** (AASU0036)

Estefany Rios Guzman  
Northwestern University, Chicago, IL, USA

**12:45 – 13:45 Lunch**

**SESSION**

**11**

**13:45 – 14:50**

**ACCESS TO CARE/GLOBAL ROLLOUT**

Co-Chairs: Helen Chu, University of Washington, Seattle, WA, USA  
and Janet Englund, Seattle Children's Hospital, Seattle, WA, USA

**13:50 – 14:15**

**Global Public Health Security and Justice for Vaccines and Therapeutics in the COVID-19 Pandemic**

Sylvie Briand  
WHO, Geneva, Switzerland

**14:15 – 14:40**

**Enabling Access to Medical Countermeasures by Underserved Populations**

Meghan Pennini  
HHS, Washington, DC, USA

**14:40 – 14:50**

**Panel Discussion**

**14:50 – 15:00**

**Summary & Close**